Wasatch Advisors LP Has $5.76 Million Position in Aquestive Therapeutics, Inc. $AQST

Key Points

• Wasatch Advisors increased its Aquestive Therapeutics position by 57.8% in the second quarter, owning 1.39 million shares valued at approximately $5.76 million, or 1.10% of the company. Institutional investors collectively own 32.45% of AQST.
• Aquestive reported quarterly revenue of $13.82 million, above estimates of $11.42 million, but its $0.18-per-share loss exceeded the expected $0.10 loss. Full-year revenue guidance of $46 million to $50 million is also below the roughly $50.8 million consensus estimate.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average target price of $8.50 versus the stock’s $4.23 opening price. However, CEO Daniel Barber and Director Julie Krop recently sold shares under pre-arranged Rule 10b5-1 plans.

Wasatch Advisors LP raised its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 57.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,385,843 shares of the company's stock after buying an additional 507,527 shares during the quarter. Wasatch Advisors LP owned 1.10% of Aquestive Therapeutics worth $5,765,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Arete Wealth Advisors LLC bought a new position in shares of Aquestive Therapeutics during the 1st quarter worth about $504,000. Bank of America Corp DE increased its stake in Aquestive Therapeutics by 99.2% in the first quarter. Bank of America Corp DE now owns 2,405,050 shares of the company's stock valued at $9,981,000 after acquiring an additional 1,197,459 shares during the period. ADAR1 Capital Management LLC increased its stake in Aquestive Therapeutics by 103.9% in the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company's stock valued at $42,000 after acquiring an additional 264,000 shares during the period. Royal Bank of Canada raised its position in Aquestive Therapeutics by 133.0% in the first quarter. Royal Bank of Canada now owns 28,951 shares of the company's stock worth $120,000 after purchasing an additional 16,525 shares in the last quarter. Finally, Quantinno Capital Management LP raised its position in Aquestive Therapeutics by 52.8% in the first quarter. Quantinno Capital Management LP now owns 18,014 shares of the company's stock worth $75,000 after purchasing an additional 6,221 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company's stock.

Insider Activity at Aquestive Therapeutics

In other news, CEO Daniel Barber sold 8,257 shares of the business's stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $4.29, for a total value of $35,422.53. Following the transaction, the chief executive officer directly owned 660,574 shares of the company's stock, valued at $2,833,862.46. The trade was a 1.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julie Krop sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total value of $125,500.00. Following the sale, the director owned 25,000 shares in the company, valued at approximately $125,500. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Wall Street Zen upgraded shares of Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aquestive Therapeutics in a research note on Friday, July 17th. Finally, Oppenheimer began coverage on Aquestive Therapeutics in a report on Friday, April 24th. They issued an "outperform" rating and a $8.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $8.50.

Aquestive Therapeutics Stock Down 4.1%

Shares of AQST stock opened at $4.23 on Thursday. Aquestive Therapeutics, Inc. has a 12-month low of $2.93 and a 12-month high of $7.55. The company has a market capitalization of $530.74 million, a P/E ratio of -6.51 and a beta of 1.49. The firm has a 50-day moving average price of $4.13 and a 200 day moving average price of $4.07.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million for the quarter, compared to analysts' expectations of $11.42 million. As a group, research analysts expect that Aquestive Therapeutics, Inc. will post -0.41 earnings per share for the current year.

More Aquestive Therapeutics News

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Second-quarter revenue rose to $13.82 million, exceeding the $11.42 million analyst consensus. Management also provided a business update focused on advancing its product pipeline and preparations for future commercialization. Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The earnings call and related coverage kept attention on Aquestive’s regulatory progress and commercial preparation. Any advancement toward approval and launch of its lead products could provide a longer-term catalyst for AQST, although investors still appear focused on execution and timing. Aquestive Therapeutics Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Reports describing a sharp increase in short interest appear unreliable: the data show zero shares short both currently and previously, with a zero-day days-to-cover ratio. This provides no meaningful indication of additional short-selling pressure.
• Negative Sentiment: Aquestive reported a second-quarter loss of $0.18 per share, wider than the expected $0.10 loss and the $0.14 loss recorded a year earlier. The earnings miss suggests that expenses and investment in development or commercialization remain elevated. Aquestive Therapeutics Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Full-year 2026 revenue guidance of $46 million to $50 million is below the approximately $50.8 million consensus estimate. The lower outlook, combined with the earnings miss, likely overshadowed the quarterly revenue beat. Aquestive Therapeutics Q2 Loss Widens, Revenue Rises

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source